Published in Int J Biochem Cell Biol on November 01, 2002
Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol (2007) 1.37
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res (2007) 1.15
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res (2005) 1.01
Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Res Treat (2011) 0.93
Risk assessment for cancer surgery in elderly patients. Clin Interv Aging (2006) 0.84
Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. Br J Cancer (2013) 0.82
Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer. Carcinogenesis (2011) 0.82
Age-associated prognostic and predictive biomarkers in patients with breast cancer. Oncol Lett (2017) 0.81
Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up. Int J Med Sci (2014) 0.78
A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget (2011) 0.76
Factors that influence the incidence of breast cancer in Arica, Chile (Review). Oncol Lett (2010) 0.76
Cardiac toxicity of trastuzumab in elderly patients with breast cancer. J Geriatr Cardiol (2016) 0.75
Clinicopathological features and treatment sensitivity of elderly Chinese breast cancer patients. Oncol Lett (2010) 0.75
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer (2006) 5.47
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007) 5.46
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem (2006) 4.59
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle (2009) 3.77
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res (2009) 3.40
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle (2009) 3.34
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med (2011) 3.16
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol (2005) 2.95
Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res (2006) 2.83
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst (2003) 2.65
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2012) 2.49
The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg (2012) 2.37
Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med (2007) 2.30
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis (2004) 2.13
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology (2012) 2.07
First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes Control (2014) 2.05
Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst (2010) 2.04
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res (2010) 1.94
Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res (2002) 1.84
Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res (2006) 1.78
Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer (2011) 1.77
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.68
Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. J Am Acad Dermatol (2008) 1.58
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat (2011) 1.55
Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer (2014) 1.55
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer (2007) 1.50
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer (2010) 1.46
Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol (2004) 1.45
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 1.42
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle (2012) 1.41
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology (2007) 1.38
Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol (2006) 1.34
Socioeconomic status in relation to early menarche among black and white girls. Cancer Causes Control (2008) 1.34
Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res (2004) 1.33
erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol (2003) 1.33
Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer (2008) 1.32
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat (2012) 1.31
Causes of physician delay in the diagnosis of breast cancer. Arch Intern Med (2002) 1.27
Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A (2006) 1.27
A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci U S A (2009) 1.27
Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach. Mol Cell Proteomics (2010) 1.26
Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer (2005) 1.25
ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res (2010) 1.24
Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol (2005) 1.23
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 1.23
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res (2008) 1.23
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther (2007) 1.22
Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab (2002) 1.21
Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer (2009) 1.20
Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res (2011) 1.20
Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res (2004) 1.20
Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol (2006) 1.18
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res (2007) 1.17
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle (2011) 1.16
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res (2007) 1.15
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat (2010) 1.14
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol (2006) 1.14
Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res (2012) 1.14
Perinucleolar compartment prevalence has an independent prognostic value for breast cancer. Cancer Res (2005) 1.14
Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol (2009) 1.12
Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol (2008) 1.11
Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res (2008) 1.11
Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol Cell Proteomics (2008) 1.11
Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. Breast Cancer Res Treat (2012) 1.10
A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics (2004) 1.10